octreotide acetate / Generic mfg. - LARVOL DELTA

177Lu-DOTATATE versus high-dose long-acting octreotide for somatostatin receptor-positive advanced GEP-NETs: A multicenter, randomised, open-label, positive-controlled phase III study (ESMO Asia 2025) - P3 | "177Lu-DOTATATE had an acceptable safety profile in GEP-NETs pts with PFS improvement versus high-dose long-acting octreotide."

Clinical • Late-breaking abstract • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • SSTR

Clinical effectiveness of everolimus plus somatostatin analogues in advanced neuroendocrine tumors: A retrospective real-world study (ESMO Asia 2025) - "Patients received either everolimus alone or in combination with a somatostatin analogue (lanreotide 120 mg Q4W or octreotide LAR 30 mg Q4W). This real-world study suggests that combining everolimus with a somatostatin analogue may improve PFS over monotherapy in advanced NETs, although statistical significance was not reached. The observed trend aligns with clinical trial data and supports the potential benefit of combination therapy in practice. No significant difference was found between lanreotide and octreotide, indicating both agents may be interchangeable when used with everolimus."

Metastases • Real-world • Real-world evidence • Retrospective data • Neuroendocrine Tumor • Oncology • Solid Tumor

Matching-adjusted indirect comparison of surufatinib versus high-dose octreotide LAR in advanced extrapancreatic neuroendocrine tumors (ESMO Asia 2025) - P3 | "This unanchored MAIC suggests surufatinib may improve survival outcomes compared to HD-OCT in advanced epNETs, with a clinically meaningful RMST advantage. The trend aligns with SANET-ep's primary results, supporting surufatinib as a viable therapeutic option."

Metastases • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

FAP-targeted Radio-ligand Therapy in Pancreatic Neuroendocrine Tumor: A Potential Alternative to PRRT. (PubMed, Clin Nucl Med) - "Initial treatment included trans-arterial embolization, long-acting octreotide, followed by chemotherapy...Subsequently, a 99mTc-FAPI-46 scan was conducted, demonstrating favorable uptake in both the liver metastases and the primary tumor, leading to the administration of 177Lu-FAPI-2286 therapy. This case highlights the potential of FAPI as a novel imaging and therapeutic strategy in the management of neuroendocrine tumors."

Journal • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

THE NEED FOR NOVEL THERAPEUTIC DIRECTIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENT CARE. (PubMed, Clin J Am Soc Nephrol) - "At present, the only drugs approved to slow disease progression are the vasopressin V2-receptor antagonist tolvaptan and, in Italy, the somatostatin analogue octreotide long-acting release for the subset of patients with stage 4 chronic kidney disease...These include not only repurposed pharmacological agents, namely sodium-glucose cotransporter-2 inhibitors, metformin, and glucagon-like peptide-1 receptor agonists, but also innovative therapies, as it is the case for a monoclonal antibody against pregnancy-associated plasma protein-A, microRNA-17 inhibitors, and the polycystin-1 correcting agent VX-407. Dietary interventions, such as caloric restriction and ketogenic diets, are being tested in clinical trials as well, and could complement pharmacotherapy to slow disease progression. Moreover, the rapid advancements in the field of gene therapy for ADPKD suggest that this approach, though as yet only explored at experimental level, could be translated into clinical..."

Journal • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • Gene Therapies • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease • MIR17 • PKD1

Hoffa's Fat Pad Impingement (HFPI) (clinicaltrials.gov) - P=N/A | N=62 | Not yet recruiting | Sponsor: Boston Children's Hospital

New trial

A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy. (PubMed, Front Cell Dev Biol) - "From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach."

Journal • Gastrointestinal Disorder • Hepatology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR • SSTR2

SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov) - P3 | N=332 | Active, not recruiting | Sponsor: Camurus AB | Trial completion date: Dec 2027 ➔ Jul 2028 | Trial primary completion date: Dec 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Neuroendocrine Tumor • Solid Tumor • SSTR

Isolated Right-Sided Heart Failure as the First Manifestation of a Pelvic Neuroendocrine Tumor: A Rare Case of Carcinoid Heart Disease in a female with no prior diagnosis of carcinoid syndrome (AHA 2025) - "She was started on octreotide LAR 20 mg every 4 weeks by Medical Oncology, evaluated by cardiothoracic surgery, and underwent surgical replacement of the aortic, tricuspid, and pulmonic valves...Primary ovarian NETs causing CHD are exceedingly rare, with only isolated case reports. Clinicians should suspect CHD in patients with right-sided heart failure, flushing, or characteristic echocardiographic findings—such as thickened valves and hepatic vein flow reversal—and confirm with elevated 5-HIAA levels."

Clinical • Carcinoid Syndrome • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastrointestinal Disorder • Heart Failure • Neuroendocrine Tumor • Oncology • Pulmonary Disease • Solid Tumor

Routine Turns Rare: Identifying a Cecal Neuroendocrine Tumor During Standard Colonoscopy (ACG 2025) - "The patient was initiated on octreotide LAR and monitored with serial serotonin and chromogranin A levels...Due to the limited number of reported cases in the literature, this case contributes valuable insight into an unusual pattern of metastatic disease. It highlights the importance of maintaining clinical vigilance during routine screening of NET patients, as early identification of atypical metastatic sites facilitates timely diagnosis and comprehensive patient management.Figure: 1 cm circumferential, umbilicated lesion with a central depression located in the cecum.Figure: Biopsy of the lesion was obtained via cold biopsy forceps and sent to pathology."

CNS Disorders • Colon Cancer • Colorectal Cancer • Depression • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Psychiatry • Solid Tumor • SYP

NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67<10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden (ESMO 2025) - P3 | "Trial design NETTER-3 is a phase III, open-label, randomized study of 177 Lu-DOTATATE + octreotide long-acting release (LAR) vs octreotide LAR in pts aged ≥12 years with newly diagnosed (≤6 months), well-differentiated, G1 and G2 (Ki-67 <10%) advanced GEP-NETs and high disease burden (investigator's opinion; guided by tumor bulk, liver involvement, disease spread, and symptoms due to tumor burden or hormone excess). Dosimetry and pharmacokinetics of 177 Lu-DOTATATE will be assessed in a subset of pts. NETTER-3 is being conducted in North America, Europe, and Asia."

Clinical • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

NETTER-3: [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, Grade 1/2 (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden (NANETS 2025) - P3 | "METHODS NETTER-3 (NCT06784752) is a Phase III, open-label, randomized study of 177Lu-DOTATATE + octreotide long-acting release (LAR) vs octreotide LAR in patients aged ≥12 years with newly diagnosed (≤6 months), well-differentiated, G1 and G2 (Ki-67 <10%) advanced GEP-NETs and high disease burden (investigator's opinion; guided by tumor bulk, liver involvement, disease spread, and symptoms due to tumor burden or hormone excess). RESULTS NETTER-3 is being conducted in North America, Europe, and Asia. CONCLUSIONS N/A"

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

Hematological Malignancy in a Hypophysectomised Acromegalic Patient Under 4-Year Therapy with Somatostatin Analogues: From a Rib Lump Underlying Bone Plasmatocytoma Features to Multiple Myeloma. (PubMed, Diagnostics (Basel)) - "A 52-year-old male with acromegaly confirmed at 46 (MRI: pituitary macroadenoma of 12 × 11 × 10 mm) underwent hypophysectomy followed by 3 years of octreotide LAR then lanreotide depot. To conclude, what started as a rather typical scenario for an otherwise rare condition, as is acromegaly in the general population (but not so rare for endocrinologists), turned into an unexpected and more severe outcome. Noting this exceptional association, we pinpoint that further research is needed for understanding the dual acromegaly-MM relationship."

Journal • Acromegaly • Bone Marrow Transplantation • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Pain • Plasmacytoma • Transplantation

Medical treatment in acromegaly: a network meta-analysis. (PubMed, Eur J Endocrinol) - "Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety and patient-specific parameters to optimize outcomes."

Journal • Retrospective data • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • Rare Diseases • IGF1

Stratification of Biochemical Response to Somatostatin Analogs in Carcinoid Syndrome: Implications for Risk of Carcinoid Heart Disease (NANETS 2025) - "METHODS We retrospectively analyzed patients with carcinoid syndrome initiated on standard-dose somatostatin analog (SA) therapy (lanreotide 120 mg SQ every 4 weeks or octreotide LAR 30 mg IM every 4 weeks)...Patients were included in the TELEHEART study and were randomized to SA + Placebo versus SA + Telotristat Ethyl...This approach enables timely consideration of adjunctive serotonin-lowering therapies for partial responders, who fail to suppress 5-HIAA below 123 ng/mL. Long-term studies can establish the survival impact of this approach."

Oncology

177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial. (PubMed, Ann Oncol) - "XTR008 monotherapy showed superior efficacy versus high-dose long-acting repeatable (LAR) octreotide monotherapy in advanced GEP-NET tumours of all origins in a later-line treatment setting, with manageable safety, supporting its use as a new treatment option."

Journal • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Continuous subcutaneous octreotide infusion in congenital hyperinsulinism: practical application and insights in infancy and early childhood. (PubMed, J Diabetes Metab Disord) - "Effective at 30mcg/kg/day, he transitioned to an infusion at 4.5 months followed by long-acting octreotide at 12 months.Both patients tolerated the infusion with no adverse effects. This report highlights the practical use of octreotide infusion via pump. When combined with CGM, it allows for tailored dosing to meet individual needs while enhancing patient convenience."

Journal

Vertebral Hemangioma in Disguise: A Ga-68 DOTATATE False Positive (EANM 2025) - "In March 2025, the patient began treatment with octreotide LAR...Vertebral hemangiomas are benign lesions typically non-avid on Ga-68 DOTATATE PET/CT but may occasionally show radiotracer uptake, mimicking metastasis. Misinterpretation of such uptake can lead to incorrect staging and management, emphasizing the importance of correlating PET/CT findings with CT or MRI to avoid misdiagnosis of skeletal metastases."

Brain Cancer • Endocrine Cancer • Lung Cancer • Meningioma • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Small Cell Lung Cancer • Solid Tumor • SSTR

A rare case of metastatic Well differentiated Neuroendocrine Tumor of Prostate on hemodialysis treated with Concurrent Long Acting Octreotide and 177Lutetitium DOTATATE therapy achieving complete response- Case report and Literature Review (EANM 2025) - "He was then advised to start treatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) along with concurrent LAR Octreotide which was challenging for the dosimetry reasons as the patient was already renal compromised and sequencing the administration of PRRT with hemodialysis. All physicians should familiarize themselves with the clinical and pathological features this histopathology, as well as the available treatment modalities, in order to prolong patient survival and enhance cure rates. Moreover, we recommend adopting a multidisciplinary approach, involving urologists, oncologists, nuclear medicine physicians and pathologists, to collaboratively discuss treatment plans and improve the health and quality of life for patients."

Case report • Clinical • Metastases • Review • Carcinoid Tumor • Chronic Kidney Disease • Endocrine Cancer • Fatigue • Hematological Disorders • Nephrology • Neuroendocrine Tumor • Neutropenia • Oncology • Pancreatic Cancer • Prostate Cancer • Renal Disease • Solid Tumor • GATA3 • KLK3 • NKX2-1 • SSTR • SYP

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Tumors, Version 3.2025. (NCCN)

NCCN guideline • Genitourinary Neuroendocrine Carcinoma • Pancreatic Neuroendocrine Tumor • Paraganglioma • Pheochromocytoma

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Completed | N=14 ➔ 19 | Trial completion date: Dec 2026 ➔ Mar 2025 | Trial primary completion date: Dec 2025 ➔ Feb 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Carcinoid Tumor • Gastrointestinal Cancer • Neuroendocrine Tumor • Solid Tumor

Circulating Tumor DNA Profiling Identifies Actionable Mutations as Prognostic Markers in Advanced Neuroendocrine Tumors. (PubMed, Neuroendocrinology) - "Higher blood tumor mutational burden (bTMB) was linked to poor prognosis in Octreotide LAR-treated patients and correlated with higher Ki-67 levels, and alterations in the TM, mTOR, and Notch pathways...TERT mutations, bTMB, and MSAF predict PFS or OS. Co-occurring TM, mTOR, and NOTCH pathway alterations highlight ctDNA's potential in guiding precision medicine."

Biomarker • Circulating tumor DNA • Journal • Tumor mutational burden • Hematological Malignancies • Neuroendocrine Tumor • Oncology • Solid Tumor • KMT2C • mTOR • NOTCH3 • SETD2 • TERT • TMB • TSC2

Experience with the Mixed Meal Test in Diagnosing GIP-Dependent Cortisol Hypersecretion at a Tertiary Center. (PubMed, Exp Clin Endocrinol Diabetes) - "The patient underwent unilateral adrenalectomy after an inadequate long-term response to octreotide LAR therapy...It is essential to further investigate which patients require screening. Moreover, a significant cortisol peak observed during the mixed meal test in the presence of these receptors has drawn attention."

Journal • Retrospective data • KDM1A

ADPKD648: Outcome of ADPKD With Octreotide LAR (clinicaltrials.gov) - P=N/A | N=70 | Active, not recruiting | Sponsor: Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • Polycystic Kidney Disease

CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial (ENDO 2025) - P3 | "CAM2029, developed using FluidCrystal® technology, is a long-acting octreotide subcutaneous depot designed for convenient self‑administration via an autoinjector pen. In ACROINNOVA 1, a 24-week (W), Phase 3 trial (NCT04076462), CAM2029 achieved superior biochemical control vs placebo (PBO; 72.2% vs 37.5%; P=0.0018) in patients previously controlled on standard of care (SoC; octreotide long-acting repeatable [LAR]/lanreotide Autogel [ATG])...The symptom burden also progressively improved with CAM2029. These results reinforce previous findings, supporting CAM2029 as a new treatment option for acromegaly."

P3 data • Acromegaly • Dermatology • Endocrine Disorders • Infectious Disease • Novel Coronavirus Disease • IGF1